G Hossein Almassi1, Todd H Wagner2, Brendan Carr3, Brack Hattler4, Joseph F Collins5, Jacquelyn A Quin6, Ramin Ebrahimi7, Frederick L Grover4, Muath Bishawi3, A Laurie W Shroyer8. 1. Zablocki Veterans Affairs Medical Center, Milwaukee, Wisconsin; Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: halmassi@mcw.edu. 2. Veterans Affairs Palo Alto Health Economics Resource Center, Menlo Park, California; Department of Health Research and Policy, Stanford University, Stanford, California. 3. Northport Veterans Affair Medical Center, Northport, New York. 4. Eastern Colorado Health Care System, Department of Veterans Affairs, Denver, Colorado; University of Colorado School of Medicine at the Anschutz Medical Campus, Aurora, Colorado. 5. Cooperative Studies Program Coordinating Center, Veterans Affairs Medical Center, Perry Point, Maryland. 6. VA Boston Healthcare System, West Roxbury, Massachusetts. 7. Greater Los Angeles VA Medical Center, Los Angeles, California. 8. Northport Veterans Affair Medical Center, Northport, New York; Eastern Colorado Health Care System, Department of Veterans Affairs, Denver, Colorado.
Abstract
BACKGROUND: New-onset postoperative atrial fibrillation (POAF) after coronary artery bypass graft surgery (CABG) is associated with worse in-hospital morbidity and mortality, extended hospital stays, and higher costs. Beyond the initial hospital discharge, the cost and outcomes of POAF have not been well studied. METHODS: For CABG patients with and without new-onset POAF, a retrospective propensity-matched, multivariable regression analysis was performed to compare 1-year outcomes (including health-related quality of life [HRQoL] scores and mortality rates) and costs (standardized to 2010 dollars). Regression models controlled for site and patient factors, with propensity matching used to adjust for differences in POAF versus no-POAF patients' risk profiles. RESULTS: Using the existing CABG trial database, 2,096 patient records were analyzed, including POAF patients (n = 549) versus no-POAF patients (n = 1,547). For the index CABG hospitalization, POAF patients had longer postoperative length of stay (+3.9 days) and higher discharge costs (+$13,993) than no-POAF patients. At 1 year, POAF patients had more than twice the adjusted odds of dying (p < 0.01), with higher 1-year total cumulative costs. This 1-year cost difference (+$15,593) was largely attributable to hospital-based costs during the index surgery hospitalization. There was no difference in 1-year HRQoL scores (or HRQoL score changes) between POAF patients and no-POAF patients. CONCLUSIONS: Compared with no-POAF patients, POAF patients had higher discharge and 1-year costs along with higher 1-year mortality rates, but no differences were observed in 1-year HRQoL scores. Additional research appears warranted to improve the longer-term survival rates for POAF CABG patients, targeting future POAF-specific postdischarge interventions.
RCT Entities:
BACKGROUND: New-onset postoperative atrial fibrillation (POAF) after coronary artery bypass graft surgery (CABG) is associated with worse in-hospital morbidity and mortality, extended hospital stays, and higher costs. Beyond the initial hospital discharge, the cost and outcomes of POAF have not been well studied. METHODS: For CABG patients with and without new-onset POAF, a retrospective propensity-matched, multivariable regression analysis was performed to compare 1-year outcomes (including health-related quality of life [HRQoL] scores and mortality rates) and costs (standardized to 2010 dollars). Regression models controlled for site and patient factors, with propensity matching used to adjust for differences in POAF versus no-POAF patients' risk profiles. RESULTS: Using the existing CABG trial database, 2,096 patient records were analyzed, including POAF patients (n = 549) versus no-POAF patients (n = 1,547). For the index CABG hospitalization, POAF patients had longer postoperative length of stay (+3.9 days) and higher discharge costs (+$13,993) than no-POAF patients. At 1 year, POAF patients had more than twice the adjusted odds of dying (p < 0.01), with higher 1-year total cumulative costs. This 1-year cost difference (+$15,593) was largely attributable to hospital-based costs during the index surgery hospitalization. There was no difference in 1-year HRQoL scores (or HRQoL score changes) between POAF patients and no-POAF patients. CONCLUSIONS: Compared with no-POAF patients, POAF patients had higher discharge and 1-year costs along with higher 1-year mortality rates, but no differences were observed in 1-year HRQoL scores. Additional research appears warranted to improve the longer-term survival rates for POAF CABG patients, targeting future POAF-specific postdischarge interventions.
Authors: X Chapalain; J F Oilleau; L Henaff; P Lorillon PharmD; D Le Saout; P Kha; K Pluchon; E Bezon; O Huet Journal: Eur Heart J Suppl Date: 2022-06-13 Impact factor: 1.624
Authors: J Hunter Mehaffey; Robert B Hawkins; Matthew Byler; Judy Smith; John A Kern; Irving Kron; Gorav Ailawadi; Tanya Wanchek; Leora T Yarboro Journal: Ann Thorac Surg Date: 2018-01-31 Impact factor: 4.330
Authors: Lucrecia M Burgos; Andreína Gil Ramírez; Leonardo Seoane; Juan F Furmento; Juan P Costabel; Mirta Diez; Daniel Navia Journal: Ann Card Anaesth Date: 2021 Oct-Dec
Authors: Yau-Lam Alex Chau; Ji Won Yoo; Ho Chuen Yuen; Khalid Bin Waleed; Dong Chang; Tong Liu; Fang Zhou Liu; Gary Tse; Sharen Lee; Ka Hou Christien Li Journal: J Geriatr Cardiol Date: 2021-05-28 Impact factor: 3.327